Medical Centre Futuremeds EOOD

Futó vizsgálatok

• Még nem toboroz

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· 3. fázis· Forrás

• Toboroz

  A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

  NCT07619131· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

  NCT07400653· 3. fázis· Forrás

• Fut, nem toboroz

  Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

  NCT07311850· 3. fázis· Forrás

• Fut, nem toboroz

  Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  NCT07284875· 3. fázis· Forrás

• Toboroz

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· 3. fázis· Forrás

• Toboroz

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· 3. fázis· Forrás

• Toboroz

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· 3. fázis· Forrás

• Toboroz

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· 3. fázis· Forrás

• Toboroz

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· 3. fázis· Forrás

• Toboroz

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· 3. fázis· Forrás

• Toboroz

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Crohn-betegség2 toboroz
• Tüdőrák2 toboroz
• Zsírmáj (MASLD/MASH)2 toboroz
• Elhízás1 toboroz
• Szarkóma1 toboroz
• Szívelégtelenség1 toboroz

Kutatók

Ide még nem kötődik kutató.